Volumetric measurement to evaluate treatment response to induction chemotherapy on MRI outperformed RECIST guideline in outcome prediction in advanced nasopharyngeal carcinoma

IF 7.1 2区 医学 Q1 ONCOLOGY ESMO Open Pub Date : 2024-10-01 DOI:10.1016/j.esmoop.2024.103933
T.S.A. Kwong , H.S. Leung , F.K.F. Mo , Y.M. Tsang , L. Lan , L.M. Wong , T.Y. So , E.P. Hui , B.B.Y. Ma , A.D. King , Q.Y.H. Ai
{"title":"Volumetric measurement to evaluate treatment response to induction chemotherapy on MRI outperformed RECIST guideline in outcome prediction in advanced nasopharyngeal carcinoma","authors":"T.S.A. Kwong ,&nbsp;H.S. Leung ,&nbsp;F.K.F. Mo ,&nbsp;Y.M. Tsang ,&nbsp;L. Lan ,&nbsp;L.M. Wong ,&nbsp;T.Y. So ,&nbsp;E.P. Hui ,&nbsp;B.B.Y. Ma ,&nbsp;A.D. King ,&nbsp;Q.Y.H. Ai","doi":"10.1016/j.esmoop.2024.103933","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Treatment response evaluated by tumour size change is an important indicator for outcome prediction. Advanced nasopharyngeal carcinoma (adNPC) grows irregularly, and so the unidimensional measurement may not be accurately applied to adNPC for outcome prediction. This study aimed to evaluate values of unidimensional and volumetric measurements for treatment response to induction chemotherapy (IC) for outcome prediction in adNPC and compared the values with that of RECIST 1.1 guideline.</div></div><div><h3>Materials and methods</h3><div>Pre-treatment and post-IC magnetic resonance images (MRIs) from 124 patients with stage III-IVA NPC were retrospectively reviewed. Sums of the maximum unidimensional diameters (D) and volumes of the targeted tumours (primary tumour and two largest metastatic lymph nodes) on the pre- (D<sub>pre</sub> and V<sub>pre</sub>) and post-IC MRIs (D<sub>post-IC</sub> and V<sub>post-IC</sub>) and percentage changes in D (Δ D%) and V (ΔV%) between two scans were calculated and correlated with disease-free survival (DFS), locoregional recurrence-free survival (LRRFS), and distant metastases-free survival (DMFS) using Cox regression analysis. Area under the curves (AUCs) of independent measurements and RECIST groups (RECIST response and non-response groups) for predicting disease recurrence, locoregional recurrence, and distant metastases, respectively, were calculated and compared using the DeLong test.</div></div><div><h3>Results</h3><div>Univariable analysis showed correlations between high D<sub>post-IC</sub> with poor DFS and DMFS (<em>P</em> &lt; 0.05), but not with LRRFS (<em>P</em> = 0.07); high V<sub>post-IC</sub> and low ΔV% (less decrease in volume on post-IC) with poor DFS, LRRFS, and DMFS (<em>P</em> &lt; 0.05); and no correlations between D<sub>pre</sub>, ΔD%, and V<sub>pre</sub> and the outcomes (<em>P</em> &gt; 0.05). Multivariable analysis showed that ΔV% was the only independent measurement for outcomes (<em>P</em> &lt; 0.05). Compared with RECIST groups, ΔV% of 47.9% (median value) showed a higher AUC for disease recurrence (0.682 versus 0.526, <em>P</em> &lt; 0.01) and for locoregional recurrence (0.782 versus 0.585, <em>P</em> &lt; 0.01), but not for distant metastases (0.593 versus 0.518, <em>P</em> = 0.26).</div></div><div><h3>Conclusions</h3><div>Volumetric measurement to evaluate treatment response to IC outperformed unidimensional measurement and RECIST guideline in outcome prediction in adNPC.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103933"},"PeriodicalIF":7.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Open","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2059702924017034","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Treatment response evaluated by tumour size change is an important indicator for outcome prediction. Advanced nasopharyngeal carcinoma (adNPC) grows irregularly, and so the unidimensional measurement may not be accurately applied to adNPC for outcome prediction. This study aimed to evaluate values of unidimensional and volumetric measurements for treatment response to induction chemotherapy (IC) for outcome prediction in adNPC and compared the values with that of RECIST 1.1 guideline.

Materials and methods

Pre-treatment and post-IC magnetic resonance images (MRIs) from 124 patients with stage III-IVA NPC were retrospectively reviewed. Sums of the maximum unidimensional diameters (D) and volumes of the targeted tumours (primary tumour and two largest metastatic lymph nodes) on the pre- (Dpre and Vpre) and post-IC MRIs (Dpost-IC and Vpost-IC) and percentage changes in D (Δ D%) and V (ΔV%) between two scans were calculated and correlated with disease-free survival (DFS), locoregional recurrence-free survival (LRRFS), and distant metastases-free survival (DMFS) using Cox regression analysis. Area under the curves (AUCs) of independent measurements and RECIST groups (RECIST response and non-response groups) for predicting disease recurrence, locoregional recurrence, and distant metastases, respectively, were calculated and compared using the DeLong test.

Results

Univariable analysis showed correlations between high Dpost-IC with poor DFS and DMFS (P < 0.05), but not with LRRFS (P = 0.07); high Vpost-IC and low ΔV% (less decrease in volume on post-IC) with poor DFS, LRRFS, and DMFS (P < 0.05); and no correlations between Dpre, ΔD%, and Vpre and the outcomes (P > 0.05). Multivariable analysis showed that ΔV% was the only independent measurement for outcomes (P < 0.05). Compared with RECIST groups, ΔV% of 47.9% (median value) showed a higher AUC for disease recurrence (0.682 versus 0.526, P < 0.01) and for locoregional recurrence (0.782 versus 0.585, P < 0.01), but not for distant metastases (0.593 versus 0.518, P = 0.26).

Conclusions

Volumetric measurement to evaluate treatment response to IC outperformed unidimensional measurement and RECIST guideline in outcome prediction in adNPC.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在晚期鼻咽癌的疗效预测方面,通过磁共振成像测量体积来评估诱导化疗的治疗反应优于RECIST指南。
背景:根据肿瘤大小变化评估治疗反应是预测疗效的重要指标。晚期鼻咽癌(adNPC)生长不规则,因此单维测量可能无法准确用于晚期鼻咽癌的疗效预测。本研究旨在评估诱导化疗(IC)治疗反应的单维测量值和容积测量值,以预测 adNPC 的治疗结果,并将其与 RECIST 1.1 指南的测量值进行比较:对124例III-IVA期鼻咽癌患者治疗前和化疗后的磁共振图像(MRI)进行回顾性研究。计算治疗前(Dpre 和 Vpre)和治疗后(Dpost-IC 和 Vpost-IC)磁共振成像上目标肿瘤(原发肿瘤和两个最大的转移淋巴结)的最大单维直径 (D) 和体积之和,以及两次扫描之间 D (Δ D%) 和 V (Δ V%) 的百分比变化,并将其与无病生存率 (DFS) 相关联、通过 Cox 回归分析,计算出两次扫描之间的无疾病生存期(DFS)、无局部复发生存期(LRRFS)和无远处转移生存期(DMFS)的百分比,并将其与无疾病生存期(DFS)相关联。使用 DeLong 检验计算并比较了独立测量值和 RECIST 组(RECIST 反应组和无反应组)预测疾病复发、局部复发和远处转移的曲线下面积(AUC):单变量分析显示,高Dpost-IC与不良DFS和DMFS相关(P < 0.05),但与LRRFS无关(P = 0.07);高Vpost-IC和低ΔV%(IC后体积减少较少)与不良DFS、LRRFS和DMFS相关(P < 0.05);Dpre、ΔD%和Vpre与结果无相关性(P > 0.05)。多变量分析表明,ΔV%是唯一与预后相关的独立测量指标(P<0.05)。与RECIST组相比,47.9%的ΔV%(中位值)在疾病复发(0.682对0.526,P<0.01)和局部复发(0.782对0.585,P<0.01)方面显示出更高的AUC,但在远处转移(0.593对0.518,P=0.26)方面却没有显示出更高的AUC:结论:用体积测量法评估对IC的治疗反应,在预测腺鼻咽癌的预后方面优于单维测量法和RECIST指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ESMO Open
ESMO Open Medicine-Oncology
CiteScore
11.70
自引率
2.70%
发文量
255
审稿时长
10 weeks
期刊介绍: ESMO Open is the online-only, open access journal of the European Society for Medical Oncology (ESMO). It is a peer-reviewed publication dedicated to sharing high-quality medical research and educational materials from various fields of oncology. The journal specifically focuses on showcasing innovative clinical and translational cancer research. ESMO Open aims to publish a wide range of research articles covering all aspects of oncology, including experimental studies, translational research, diagnostic advancements, and therapeutic approaches. The content of the journal includes original research articles, insightful reviews, thought-provoking editorials, and correspondence. Moreover, the journal warmly welcomes the submission of phase I trials and meta-analyses. It also showcases reviews from significant ESMO conferences and meetings, as well as publishes important position statements on behalf of ESMO. Overall, ESMO Open offers a platform for scientists, clinicians, and researchers in the field of oncology to share their valuable insights and contribute to advancing the understanding and treatment of cancer. The journal serves as a source of up-to-date information and fosters collaboration within the oncology community.
期刊最新文献
Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study☆ Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study☆ Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial A machine learning-based analysis of nationwide cancer comprehensive genomic profiling data across cancer types to identify features associated with recommendation of genome-matched therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1